Latest News

Stay updated with our latest research, press releases, and industry coverage as we advance innovative fibrosis treatments.

News

Southern Research awards biotech funds, bringing new jobs and business to Alabama

Southern Research has awarded more than $2.7 million in funds to eight biotech companies through a fund established as a result of the Innovate Alabama Tax Credit.

Read more
News

Biotech incubator Station 41 fills up with plans to expand

Southern Research’s biotech incubator, Station 41 fills up with plans to expand.

Read more
News

Why an Ohio-based company made the move to Southern Research's Station 41

A company launched from an Ohio-based research firm saw the innovation happening in Birmingham and came here to be a part of it.

Read more
News

Southern Research awards biotech funds

Southern Research, a non-profit scientific research organization focused on green energy and medical advancements, announced the awards and said the initial investments should add about two dozen high-paying jobs in the state.

Read more
Publication

Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism

Thrombospondin (TSP) forms specific complexes with transforming growth factor-beta (TGF-beta) in the alpha granule releasate of platelets and these TSP-TGF-beta complexes inhibit the growth of bovine aortic endothelial cells (BAE).

Read more
Publication

Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1

Transforming growth factor-beta (TGF-beta) is a potent growth regulatory protein secreted by virtually all cells in a latent form.

Read more
Publication

Thrombospondin-1 is a major activator of TGF-beta1 in vivo

The activity of TGF-beta1 is regulated primarily extracellularly where the secreted latent form must be modified to expose the active molecule. Here we show that thrombospondin-1 is responsible for a significant proportion of the activation of TGF-beta1 in vivo.

Read more
Publication

The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta

One of the primary points of regulation of transforming growth factor-beta (TGF-beta) activity is control of its conversion from the latent precursor to the biologically active form.

Read more
Publication

Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo

Transforming growth factor-beta (TGF-beta), a profibrotic cytokine involved in many scarring processes, has to be activated extracellularly before it can bind to its receptors.

Read more
Publication

A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II

In diabetes and hypertension, the induction of increased transforming growth factor-beta (TGF-beta) activity due to glucose and angiotensin II is a significant factor in the development of fibrosis and organ failure.

Read more
Publication

Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo

Transforming growth factor-beta (TGF-beta), the central cytokine responsible for the development of diabetic nephropathy, is usually secreted as a latent procytokine complex that has to be activated before it can bind to its receptors.

Read more
Publication

Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy

Transforming growth factor-β (TGF-β) is key in the pathogenesis of diabetic nephropathy. Thrombospondin 1 (TSP1) expression is increased in diabetes, and TSP1 regulates latent TGF-β activation in vitro and in diabetic animal models.

Read more
Publication

Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma

Transforming growth factor (TGF)-β supports multiple myeloma progression and associated osteolytic bone disease.

Read more
Publication

Identification of Inhibitors of Thrombospondin 1 Activation of TGF-βArticle link copied!

TGF-β has been a target of interest for the treatment of fibrotic diseases and certain cancers. Approaches to target TGF-β include antagonists of the active ligand or TGF-β receptor kinase activity.

Read more
Publication

Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease

Transforming growth factor-β (TGF-β) is a central player in fibrotic disease. Clinical trials with global inhibitors of TGF-β have been disappointing, suggesting that a more targeted approach is warranted.

Read more

Have Questions or Need More Information?

If you have any questions or would like more information about DomainOne Therapeutics, feel free to reach out to us. We’re here to help.

Contact Us